PE20110807A1 - Inhibidores de cinasa akt y p70 s6 - Google Patents

Inhibidores de cinasa akt y p70 s6

Info

Publication number
PE20110807A1
PE20110807A1 PE2011001018A PE2011001018A PE20110807A1 PE 20110807 A1 PE20110807 A1 PE 20110807A1 PE 2011001018 A PE2011001018 A PE 2011001018A PE 2011001018 A PE2011001018 A PE 2011001018A PE 20110807 A1 PE20110807 A1 PE 20110807A1
Authority
PE
Peru
Prior art keywords
piperidin
pirrolo
ona
imidazol
pyrimidin
Prior art date
Application number
PE2011001018A
Other languages
English (en)
Spanish (es)
Inventor
Robert Dean Dally
Sajan Joseph
Timothy Alan Shepherd
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20110807A1 publication Critical patent/PE20110807A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PE2011001018A 2008-11-11 2009-11-03 Inhibidores de cinasa akt y p70 s6 PE20110807A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11

Publications (1)

Publication Number Publication Date
PE20110807A1 true PE20110807A1 (es) 2011-10-31

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001018A PE20110807A1 (es) 2008-11-11 2009-11-03 Inhibidores de cinasa akt y p70 s6

Country Status (36)

Country Link
US (1) US8148387B2 (OSRAM)
EP (1) EP2358710B1 (OSRAM)
JP (1) JP5432275B2 (OSRAM)
KR (1) KR101334460B1 (OSRAM)
CN (1) CN102216302B (OSRAM)
AR (1) AR074072A1 (OSRAM)
AU (1) AU2009314324B2 (OSRAM)
BR (1) BRPI0921916A2 (OSRAM)
CA (1) CA2743019C (OSRAM)
CO (1) CO6382114A2 (OSRAM)
CR (1) CR20110240A (OSRAM)
CY (1) CY1113409T1 (OSRAM)
DK (1) DK2358710T3 (OSRAM)
DO (1) DOP2011000129A (OSRAM)
EA (1) EA018947B1 (OSRAM)
EC (1) ECSP11011048A (OSRAM)
ES (1) ES2391704T3 (OSRAM)
HN (1) HN2011001247A (OSRAM)
HR (1) HRP20120738T1 (OSRAM)
IL (1) IL211940A (OSRAM)
JO (1) JO2822B1 (OSRAM)
MA (1) MA32776B1 (OSRAM)
MX (1) MX2011005000A (OSRAM)
MY (1) MY161461A (OSRAM)
NZ (1) NZ592062A (OSRAM)
PA (1) PA8846901A1 (OSRAM)
PE (1) PE20110807A1 (OSRAM)
PL (1) PL2358710T3 (OSRAM)
PT (1) PT2358710E (OSRAM)
RS (1) RS52520B (OSRAM)
SI (1) SI2358710T1 (OSRAM)
TN (1) TN2011000207A1 (OSRAM)
TW (1) TWI422587B (OSRAM)
UA (1) UA100190C2 (OSRAM)
WO (1) WO2010056563A1 (OSRAM)
ZA (1) ZA201102549B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597579A (en) 2009-07-02 2013-06-28 Sanofi Sa Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
CN102574852B (zh) * 2009-10-23 2014-06-25 伊莱利利公司 Akt抑制剂
PT2694510E (pt) 2011-04-07 2016-02-08 Bayer Pharma AG Imidazopiridazinas como inibidores da akt quinase
JP5695800B2 (ja) * 2011-07-09 2015-04-08 山東軒竹医薬科技有限公司 ジペプチジルペプチダーゼ−iv阻害剤の塩の結晶形i、及びその製造方法並びにその応用
DK2755958T3 (en) 2011-09-12 2017-09-25 Merck Patent Gmbh AMINOPYRIMIDINE DERIVATIVES USED AS MODULATORS OF KINASE ACTIVITY
US9145392B2 (en) * 2011-09-12 2015-09-29 Merck Patent Gmbh Imidazole amines as modulators of kinase activity
CN105102435A (zh) 2012-11-16 2015-11-25 默克专利有限公司 用作激酶活性调节剂的新颖的咪唑-哌啶基衍生物
CA2890288A1 (en) * 2012-11-16 2014-05-22 Merck Patent Gmbh Novel heterocyclic derivatives as modulators of kinase activity
HK1218756A1 (zh) * 2013-03-11 2017-03-10 默克专利有限公司 用作激酶活性调节剂的6-[4-(1h-咪唑-2-基)哌啶-1-基]嘧啶-4-胺衍生物
RU2690679C2 (ru) * 2014-02-11 2019-06-05 Мерк Патент Гмбх Новые пиримидинимидазоламины в качестве модуляторов активности киназы
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
JP6576553B2 (ja) 2016-05-20 2019-09-18 大鵬薬品工業株式会社 新規5H−ピロロ[2,3−d]ピリミジン−6(7H)−オン誘導体
CN118530260A (zh) * 2020-03-17 2024-08-23 江苏恒瑞医药股份有限公司 稠合二环类衍生物、其制备方法及其在医药上的应用
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
US20250145641A1 (en) 2021-09-17 2025-05-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused bicyclic derivative, pharmaceutically acceptable salt, crystal form thereof and preparation method therefor
CN119403807A (zh) * 2022-07-05 2025-02-07 大鹏药品工业株式会社 5H-吡咯并[2,3-d]嘧啶-6(7H)-酮及其盐体的结晶

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス, インコーポレイテッド キナーゼ調節因子および使用方法
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
JP5114395B2 (ja) 2005-06-30 2013-01-09 プロシディオン・リミテッド Gpcrアゴニスト
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
EA201170680A1 (ru) 2011-12-30
CN102216302B (zh) 2013-08-21
EP2358710A1 (en) 2011-08-24
TN2011000207A1 (en) 2012-12-17
CY1113409T1 (el) 2016-06-22
DK2358710T3 (da) 2012-09-03
CA2743019A1 (en) 2010-05-20
AU2009314324A1 (en) 2010-05-20
SI2358710T1 (sl) 2012-11-30
US8148387B2 (en) 2012-04-03
HK1158203A1 (en) 2012-07-13
MY161461A (en) 2017-04-14
CO6382114A2 (es) 2012-02-15
CR20110240A (es) 2011-06-09
NZ592062A (en) 2013-03-28
JO2822B1 (en) 2014-09-15
JP2012508274A (ja) 2012-04-05
MX2011005000A (es) 2011-05-25
HN2011001247A (es) 2013-05-20
UA100190C2 (en) 2012-11-26
WO2010056563A1 (en) 2010-05-20
PL2358710T3 (pl) 2012-12-31
PT2358710E (pt) 2012-10-01
HRP20120738T1 (hr) 2012-10-31
IL211940A0 (en) 2011-06-30
IL211940A (en) 2014-01-30
DOP2011000129A (es) 2016-02-29
ZA201102549B (en) 2012-09-26
AU2009314324B2 (en) 2013-06-20
MA32776B1 (fr) 2011-11-01
CN102216302A (zh) 2011-10-12
EA018947B1 (ru) 2013-11-29
BRPI0921916A2 (pt) 2015-12-29
ECSP11011048A (es) 2011-06-30
ES2391704T3 (es) 2012-11-29
KR20110074578A (ko) 2011-06-30
EP2358710B1 (en) 2012-08-15
TW201022268A (en) 2010-06-16
KR101334460B1 (ko) 2013-12-02
AR074072A1 (es) 2010-12-22
JP5432275B2 (ja) 2014-03-05
CA2743019C (en) 2013-08-13
TWI422587B (zh) 2014-01-11
RS52520B (sr) 2013-04-30
PA8846901A1 (es) 2010-06-28
US20100120801A1 (en) 2010-05-13

Similar Documents

Publication Publication Date Title
PE20110807A1 (es) Inhibidores de cinasa akt y p70 s6
PE20141681A1 (es) Inhibidores de btk
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
NZ594597A (en) Substituted piperidines as ccr3 antagonists
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
PE20091035A1 (es) Derivados de 2-aminopirimidina
NO20065626L (no) 4-fenylamino-quinazolin-6-yl-amider
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
HRP20140252T1 (hr) Derivati imidazola kao inhibitori kazeinske kinaze
AR071763A1 (es) Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos
WO2008148868A8 (en) Piperidine/piperazine derivatives
PE20120635A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20090773A1 (es) Derivados de morfolina pirimidina
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
NO20082388L (no) Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer
PE20130774A1 (es) Compuestos heterociclicos activadores de ampk y metodos para emplearlos
PE20191757A1 (es) Compuestos heterociclicos utiles como inhibidores dobles de atx/ca
PE20120321A1 (es) Indazoles sustituidos con oxazol como inhibidores de pi3-quinasa
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
PE20120356A1 (es) Compuestos para el tratamiento de trastornos metabolicos
PE20080405A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb
PE20091433A1 (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177
SV2010003723A (es) Derivados de piperidina 3,4-sustituida como inhibidores de renina
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed